Asunaprevir Pharmacokinetics and Safety in Subjects With Impaired Renal Function

被引：0

作者：

Garimella, Tushar ^{[1
]}

He, Bing ^{[1
]}

Luo, Wen-Lin ^{[2
]}

Colston, Elizabeth ^{[1
]}

Zhu, Kurt ^{[1
]}

Kandoussi, Hamza ^{[2
]}

Marbury, Thomas C. ^{[3
]}

Alcorn, Harry W. ^{[4
]}

Smith, William B. ^{[5
]}

Eley, Timothy ^{[1
]}

机构：

[1] Bristol Myers Squibb Co, Res & Dev, Hopewell, NJ USA

[2] Bristol Myers Squibb Co, Res & Dev, Lawrenceville, NJ USA

[3] Orlando Clin Res Ctr, Orlando, FL USA

[4] DaVita Clin Res, Minneapolis, MN USA

[5] New Orleans Ctr Clin Res, Knoxville, TN USA

来源：

HEPATOLOGY | 2013年 / 58卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

463

引用

页码：430A / 430A

页数：1

共 50 条

[11] Pharmacokinetics of glucarpidase in subjects with normal and impaired renal function
Phillips, Marc
Smith, William
Balan, Guhan
Ward, Suzanne
[J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (03): : 279 - 284
[12] AN OPEN-LABEL STUDY TO DETERMINE THE SAFETY AND PHARMACOKINETICS OF AT1001 IN SUBJECTS WITH IMPAIRED RENAL FUNCTION AND HEALTHY SUBJECTS WITH NORMAL RENAL FUNCTION
Johnson, F. K.
Mudd, P. N., Jr.
Sitaraman, S.
Boudes, P.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S85 - S85
[13] An Open-Label Study to Determine the Pharmacokinetics and Safety of Migalastat HCl in Subjects With Impaired Renal Function and Healthy Subjects With Normal Renal Function
Johnson, Franklin K.
Mudd, Paul N., Jr.
DiMino, Tara
Vosk, Jennie
Sitaraman, Sheela
Boudes, Pol
France, Nicholas
Barlow, Carrolee
[J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2015, 4 (04): : 256 - 261
[14] Pharmacokinetics, Pharmacodynamics, and Safety of Peginterferon Beta-1a in Subjects with Normal or Impaired Renal Function
Hu, Xiao
Seddighzadeh, Ali
Stecher, Scott
Zhu, Ying
Goyal, Jaya
Matson, Mark
Marbury, Thomas
Smith, William
Nestorov, Ivan
Hung, Serena
[J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 55 (02): : 179 - 188
[15] Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function
Nagy, CF
Kumar, D
Cullen, EI
Bolton, WK
Marbury, TC
Gutierrez, MJ
Hutman, HW
Pratt, RD
[J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 58 : 18 - 24
[16] PHARMACOKINETICS OF CEFOTAXIME IN SUBJECTS WITH NORMAL AND IMPAIRED RENAL-FUNCTION
FILLASTRE, JP
LEROY, A
HUMBERT, G
GODIN, M
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1980, 6 : 103 - 111
[17] PHARMACOKINETICS OF MOXALACTAM IN SUBJECTS WITH NORMAL AND IMPAIRED RENAL-FUNCTION
LEROY, A
HUMBERT, G
FILLASTRE, JP
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1981, 19 (06) : 965 - 971
[18] LOMEFLOXACIN PHARMACOKINETICS IN SUBJECTS WITH NORMAL AND IMPAIRED RENAL-FUNCTION
LEROY, A
FILLASTRE, JP
HUMBERT, G
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (01) : 17 - 20
[19] PHARMACOKINETICS OF NAPROXEN IN SUBJECTS WITH NORMAL AND IMPAIRED RENAL-FUNCTION
ANTTILA, M
HAATAJA, M
KASANEN, A
[J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 18 (03) : 263 - 268
[20] PHARMACOKINETICS OF AZLOCILLIN IN SUBJECTS WITH NORMAL AND IMPAIRED RENAL-FUNCTION
LEROY, A
HUMBERT, G
GODIN, M
FILLASTRE, JP
[J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1980, 17 (03) : 344 - 349

← 1 2 3 4 5 →